#185 – Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way we assess risk
“If we’re still saying the same things we said 30 years ago, it could be a problem because we should have learned how to say it better, more accurately.” —Allan Sniderman
Does low cholesterol cause cognitive impairment? Part II
Safety of lipid-lowering therapy
Does low cholesterol cause cognitive impairment? Part I
Safety of lipid-lowering therapy
Measuring cardiovascular disease risk and the importance of apoB
Millions of Americans schedule an annual physical health examination. During their visit, many can expect to get their blood drawn for…
LDL-C & systolic blood pressure and lifetime risk of cardiovascular disease
Mendelian randomization and lifetime cardiovascular disease risk.
#21 – Tom Dayspring, M.D., FACP, FNLA – Part II of V: Lipid metrics, lipid measurements, and cholesterol regulation
“If you learn nothing else today, the first thing is, lipids, for the most part, go nowhere in the human body unless they’re a passenger inside a lipoprotein.” –Tom Dayspring
Narrative glossary: lipids
A companion post for the podcast episodes with Thomas Dayspring, M.D., FACP, FNLA (October 15-19, 2018).
#19 – Dave Feldman: stress testing the lipid energy model
“I am on a journey of science, not of advocacy: I’m going to be quite a skeptic.” —Dave Feldman
Transcript — The Drive — Dave Feldman
Transcript of episode 19 of The Drive with Peter Attia, released October 8, 2018.
When does heart disease begin (and what this tells us about prevention)?
Before I get into this post I want to lay a few things out.